Professional Marketing briefs: October 2013

Professional Marketing briefs: October 2013
Professional Marketing briefs: October 2013
San Antonio-based Mission Pharmacal has created a new sales force to promote its line of urology medicines. A company announcement noted that the new lineup is a revival of the days when it used to have distinct urology and women's healthcare sales forces. The urology-only reps are a mix of now-former Women's Health/Urology reps and newly onboarded team members.

Lundbeck is readying a staff of more than 200 sales reps in anticipation of regulatory approval of its anti-depressant ­Brintellix, reports Bloomberg. Denmark's second-biggest drug maker could not share details regarding whether these will be in-house or contract reps, but a Takeda spokesperson tells MM&M the co-promote agreement with Takeda will leverage Lundbeck's experience working with CNS HCPs and Takeda's foundation in primary care. The FDA is scheduled to vote on the drug by October 2.

Boehringer Ingelheim is cutting jobs abroad, and sales roles are part of the headcount. PMLive reports that the company is eliminating 143 sales positions, the majority of the 178 jobs that are being cut as part of the reorganization. The remaining 35 jobs are administrative roles.

You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.